Brainsway Ltd (BWAY)vsEdwards Lifesciences Corp (EW)
BWAY
Brainsway Ltd
$13.57
-0.29%
HEALTHCARE · Cap: $560.10M
EW
Edwards Lifesciences Corp
$88.34
+0.09%
HEALTHCARE · Cap: $50.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 10630% more annual revenue ($6.51B vs $60.70M). BWAY leads profitability with a 15.6% profit margin vs 15.4%. EW trades at a lower P/E of 52.5x. EW earns a higher WallStSmart Score of 55/100 (C).
BWAY
Buy50
out of 100
Grade: C-
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BWAY.
Margin of Safety
+68.8%
Fair Value
$254.09
Current Price
$88.34
$165.75 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.4% year-over-year
Earnings expanding 64.6% YoY
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Strong operational efficiency at 29.8%
Areas to Watch
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Distress zone — elevated risk
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : BWAY
The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 14.0%. Revenue growth of 35.4% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : BWAY
The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 60.6x leaves little room for execution misses.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 52.5x leaves little room for execution misses.
Key Dynamics to Monitor
BWAY profiles as a growth stock while EW is a mature play — different risk/reward profiles.
EW carries more volatility with a beta of 0.85 — expect wider price swings.
BWAY is growing revenue faster at 35.4% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 50/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Brainsway Ltd
HEALTHCARE · MEDICAL DEVICES · USA
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?